Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma

Background - Severe injury and associated hemorrhagic shock lead to an inflammatory response and subsequent increased tissue damage. Numerous reports have shown that injury-induced inflammation and the associated end-organ damage is driven by Toll-like receptor 4 (TLR4) activation via damage-associa...

Full description

Saved in:
Bibliographic Details
Main Authors: Korff, Sebastian (Author) , Loughran, Patricia (Author) , Cai, Chanchun (Author) , Lee, Yi Shan (Author) , Scott, Melanie (Author) , Billiar, Timothy R. (Author)
Format: Article (Journal)
Language:English
Published: 27 March 2013
In: Journal of surgical research
Year: 2013, Volume: 184, Issue: 2, Pages: e17-e25
ISSN:1095-8673
DOI:10.1016/j.jss.2013.03.023
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jss.2013.03.023
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0022480413002187
Get full text
Author Notes:Sebastian Korff, Patricia Loughran, Chanchun Cai, Yi Shan Lee, Melanie Scott, and Timothy R. Billiar, MD
Description
Summary:Background - Severe injury and associated hemorrhagic shock lead to an inflammatory response and subsequent increased tissue damage. Numerous reports have shown that injury-induced inflammation and the associated end-organ damage is driven by Toll-like receptor 4 (TLR4) activation via damage-associated molecular patterns. We examined the effectiveness of Eritoran tetrasodium (E5564), an inhibitor of TLR4 function, in reducing inflammation induced during hemorrhagic shock with resuscitation (HS/R) or after peripheral tissue injury (bilateral femur fracture, BFF). - Material and methods - Mice underwent HS/R or BFF with or without injection of Eritoran (5 mg/kg body weight) or vehicle control given before, both before and after, or only after HS/R or BFF. Mice were sacrificed after 6 h and plasma and tissue cytokines, liver damage (histology; aspartate aminotransferase/alanine aminotransferase), and inflammation (NF-κB) and gut permeability were assessed. - Results - In HS/R Eritoran significantly reduced liver damage (values ± SEM: alanine aminotransferase 9910 ± 3680 U/L versus 1239 ± 327 U/L and aspartate aminotransferase 5863 ± 2000 U/L versus 1246 ± 243 U/L, P < 0.01) at 6 h compared with control when given just before HS and again just prior to resuscitation. Eritoran administration also led to lower IL-6 levels in plasma and liver and less NF-κB activation in liver. Increases in gut barrier permeability induced by HS/R were also prevented with Eritoran. Eritoran similarly diminished BFF-mediated systemic inflammatory responses. - Conclusion - These data suggest Eritoran can inhibit tissue damage and inflammation induced via TLR4/myeloid differentiation factor 2 signaling from damage-associated molecular patterns released during HS/R or BFF. Eritoran may represent a promising therapeutic for trauma patients to prevent multiple organ failure.
Item Description:Gesehen am 01.12.2021
Physical Description:Online Resource
ISSN:1095-8673
DOI:10.1016/j.jss.2013.03.023